Literature DB >> 17662585

Life and death during hematopoietic differentiation.

Joseph T Opferman1.   

Abstract

During hematopoiesis, members of the Bcl-2 family are essential regulators of homeostasis determining the survival and differentiation of progenitors. Aberrations in their expression promote pathological conditions including immune deficiency, autoimmunity, and cancer. Over the past two years, several new roles for Bcl-2 family members have been identified during hematopoietic differentiation. Anti-apoptotic Mcl-1 has been identified to be the essential pro-survival molecule during early hematopoiesis. Later in myeloid development Mcl-1 exhibits a selective role being required for the terminal stages of granulocyte development but is dispensable for monocytic differentiation. During red blood cell development, the pro-apoptotic BH3-only family member Nix has recently been defined as the essential negative regulator of terminal erythrocyte differentiation. This review will address the apoptotic pathways that regulate these critical control points during hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662585     DOI: 10.1016/j.coi.2007.06.002

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  28 in total

1.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

Review 2.  Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease.

Authors:  Sarah Fox; Andrew E Leitch; Rodger Duffin; Christopher Haslett; Adriano G Rossi
Journal:  J Innate Immun       Date:  2010-02-11       Impact factor: 7.349

3.  MCL-1 localizes to sites of DNA damage and regulates DNA damage response.

Authors:  Sarwat Jamil; Cezar Stoica; Tillie-Louise Hackett; Vincent Duronio
Journal:  Cell Cycle       Date:  2010-07-11       Impact factor: 4.534

4.  Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages.

Authors:  T Kodama; H Hikita; T Kawaguchi; M Shigekawa; S Shimizu; Y Hayashi; W Li; T Miyagi; A Hosui; T Tatsumi; T Kanto; N Hiramatsu; K Kiyomizu; S Tadokoro; Y Tomiyama; N Hayashi; T Takehara
Journal:  Cell Death Differ       Date:  2012-07-13       Impact factor: 15.828

5.  A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.

Authors:  Liang Li; Hardik Modi; Tinisha McDonald; John Rossi; Jiing-Kuan Yee; Ravi Bhatia
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

Review 6.  Subsets, expansion and activation of myeloid-derived suppressor cells.

Authors:  Eliana Ribechini; Verena Greifenberg; Sarah Sandwick; Manfred B Lutz
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

Review 7.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

Review 8.  Getting away with murder: how does the BCL-2 family of proteins kill with immunity?

Authors:  Thibaud T Renault; Jerry E Chipuk
Journal:  Ann N Y Acad Sci       Date:  2013-03-25       Impact factor: 5.691

9.  Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.

Authors:  Stefanie Slezak; Ping Jin; Lorraine Caruccio; Jiaqiang Ren; Michael Bennett; Nausheen Zia; Sharon Adams; Ena Wang; Joao Ascensao; Geraldine Schechter; David Stroncek
Journal:  J Transl Med       Date:  2009-06-04       Impact factor: 5.531

10.  Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis.

Authors:  Caroline Morel; Scott M Carlson; Forest M White; Roger J Davis
Journal:  Mol Cell Biol       Date:  2009-05-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.